Arrowhead Pharmaceuticals Faces Pivotal Regulatory Week

Investors in Arrowhead Pharmaceuticals are bracing for significant volatility as the biotechnology firm approaches two major regulatory events that could dramatically influence its valuation. The company stands at a critical juncture with an imminent FDA verdict on its drug Plozasiran while simultaneously unveiling groundbreaking cardiovascular data for Zodasiran.

While the November 18 FDA decision regarding Plozasiran dominates investor attention, Arrowhead is making substantial progress in other therapeutic areas. Today, during the American Heart Association’s Scientific Sessions, the company revealed innovative study designs for Zodasiran targeting both adolescent and adult populations. This development positions Arrowhead’s cardiovascular portfolio as a potential second revenue stream alongside its established liver disease treatments.

The Read more...